Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in
Pharmacopedia is being built in public. Pages may be incomplete.About this site

Choose a table:


Medicines > classes : Phenethylamine or Stimulant or [[:Category:Antiglaucoma medicines|Antiglaucoma medicine]]

Use the filters below to narrow your results.

generic:
brand:
None (67) · Benzedrex (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Timoptic (ophthalmic), Timoptic-XE (gel-forming once-daily), Istalol (once-daily 0.5%), Betimol; Blocadren (oral, discontinued in many markets); combination eye drops Combigan (with brimonidine), Cosopt (with dorzolamide) (1)
classes: (Click arrow to add another value)
mechanism:
5-HT2A agonist (12) · Monoamine releasing agent (8) · Dopamine/norepinephrine reuptake inhibitor (5) · Potent 5-HT2A agonist (5) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · Norepinephrine–dopamine reuptake inhibitor (2)
uses:
None (69) · '"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"' (1)
starting dose:
None (69) · Ophthalmic: 1 drop 0.5% in affected eye(s) BID (or once daily for XE / Istalol). Oral hypertension: 10 mg PO BID, titrate to 60 mg/day. Migraine prophylaxis: 10 mg BID, titrate to 30 mg/day (1)
preparations:
None (69) · Tablets 5, 10, 20 mg; ophthalmic solution 0.25%, 0.5%; ophthalmic gel-forming solution 0.25%, 0.5% (Timoptic-XE) (1)
fda max:
None (69) · 60 mg/day (oral, hypertension); 0.5% BID (ophthalmic) (1)
routes:
None (68) · insufflated (1) · ophthalmic (1) · Oral (2) · PR (1)
onset:
None (68) · 45-75 min (oral) (1) · BP effect within hours (oral); IOP reduction within 30 minutes, full effect 1-2 weeks (ophthalmic) (1)
duration:
None (68) · 12 hours (oral BID); 24 hours (Timoptic-XE) (1) · 4-8 h (1)
halflife:
None (68) · Not well characterized (1) · ~4 hours (oral)'"`UNIQ--ref-0000001B-QINU`"' (1)
bioavailability:
None (68) · Not well characterized (1) · ~50% (oral); systemic absorption from ophthalmic application is clinically meaningful via nasolacrimal drainage'"`UNIQ--ref-0000001C-QINU`"' (1)
pregnancy:
None (68) · Limited human data; β-blocker class effects include fetal growth restriction and neonatal bradycardia/hypoglycemia.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not established (1)
legal:
None (68) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US (1)

Showing below up to 70 results in range #1 to #70.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"